An­thos to stop fac­tor XI tri­al in atri­al fib­ril­la­tion ear­ly af­ter 'over­whelm­ing ben­e­fit'

An­thos Ther­a­peu­tics an­nounced Mon­day morn­ing that it is stop­ping a Phase II study of its next-gen­er­a­tion an­ti­co­ag­u­lant abelacimab in atri­al fib­ril­la­tion as a re­sult of “over­whelm­ing ben­e­fit.”

The de­ci­sion came af­ter an in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee rec­om­mend­ed the com­pa­ny and its aca­d­e­m­ic col­lab­o­ra­tor — the TI­MI Study Group from Brigham and Women’s Hos­pi­tal and Har­vard — to stop the study ear­ly since pa­tients in the treat­ment arm saw a sub­stan­tial re­duc­tion in bleed­ing events com­pared to those in the con­trol arm, who re­ceived John­son & John­son’s Xarel­to.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER